[go: up one dir, main page]

WO2016114860A1 - Quinones pour la protection contre une exposition à des rayonnements - Google Patents

Quinones pour la protection contre une exposition à des rayonnements Download PDF

Info

Publication number
WO2016114860A1
WO2016114860A1 PCT/US2015/063824 US2015063824W WO2016114860A1 WO 2016114860 A1 WO2016114860 A1 WO 2016114860A1 US 2015063824 W US2015063824 W US 2015063824W WO 2016114860 A1 WO2016114860 A1 WO 2016114860A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
hydroquinone
sat
compounds
unsat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/063824
Other languages
English (en)
Inventor
Guy M. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edison Phamaceuticals Inc
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Priority to JP2017536942A priority Critical patent/JP2018502127A/ja
Publication of WO2016114860A1 publication Critical patent/WO2016114860A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • compositions and methods useful for treating or for protecting organisms against damage caused by exposure to radiation discloses compositions and methods useful for treating or for protecting organisms against damage caused by exposure to radiation.
  • Exposure to radiation is a well-known cause of damage to cells, tissues, and organisms.
  • Ionizing radiation such as high-frequency ultraviolet radiation, X-rays, gamma rays, alpha radiation, and beta radiation can break chemical bonds, leading to damage to biological molecules in cells. Damage to DNA is particularly deleterious, and is known to cause cancer and other pathologies. Further discussion of these effects can be found in, for example, International Patent Publication WO 2010/045220.
  • Exposure to ionizing radiation may occur during medical procedures, such as radiography, fluoroscopy, dental X-rays, and CT scans. People who routinely work with radiation or radioactive materials, such as X-ray technicians or nuclear medicine specialists, may also be inadvertently exposed to radiation. Exposure to radiation may also occur due to accidental release of radioactive materials into the environment, such as the 2011 Fukushima disaster or the 1979 Three Mile Island accident, or deliberate release of radioactive materials such as a "dirty bomb.”
  • the present invention provides, in some embodiments, compounds and compositions for use in treating or protecting against injury or damage caused by radiation exposure, and methods of using such compounds for treating or for protecting against injury or damage caused by radiation exposure.
  • the present invention provides, in some embodiments, methods of using one or more compounds or compositions of Formula I, Formula I-Unsat, Formula I-Sat, Formula II, Formula II-Unsat, Formula II-Sat, Formula III, Formula III-Unsat, Formula Ill-Sat, Formula IV, Formula IV-Unsat, Formula IV-Unsat-R, Formula IV-Unsat-S, Formula IV-Sat, Formula IV-Sat-R, Formula IV-Sat-S, Formula V, Formula V-Unsat, Formula V-Sat, Formula VI, Formula Vl-Unsat, Formula VI-Unsat-R, Formula Vl-Unsat-S, Formula Vl-Sat, Formula VI- Sat-R, and Formula Vl-Sat-S, or a hydroquinone of any of those formulas, and tocotrienol quinones, tocotrienol hydroquinones, tocopherol quinones, and tocopherol hydroquinones disclosed herein, or a stereoisomer,
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure. In another embodiment, the one or more compounds are used prophylactically prior to radiation exposure. In another embodiment, the one or more compounds are administered concurrently with radiation exposure. In another embodiment, the one or more compounds are
  • the present invention provides, in some embodiments, methods of using one or more compounds or compositions of Formula I, Formula I-Unsat, Formula I-Sat, Formula II, Formula II-Unsat, Formula II-Sat, Formula III, Formula III-Unsat, Formula Ill-Sat, Formula IV, Formula IV-Unsat, Formula IV-Unsat-R, Formula IV-Unsat-S, Formula IV-Sat, Formula IV-Sat-R, Formula IV-Sat-S, Formula V, Formula V-Unsat, Formula V-Sat, Formula VI, Formula Vl-Unsat, Formula VI-Unsat-R, Formula Vl-Unsat-S, Formula Vl-Sat, Formula VI- Sat-R, and Formula Vl-Sat-S, or a hydroquinone of any of those formulas, and tocotrienol quinones, tocotrienol hydroquinones, tocopherol quinones, and tocopherol hydroquinones disclosed herein, or a stereoisomer,
  • the invention embraces a method of reducing the effect of ionizing radiation on normal cells in a subject exposed to or at risk of incurring exposure to ionizing radiation comprising administering to said subject prior to, concurrently with, or after the exposure to radiation, a therapeutically effective amount or a prophylactically effective amount of a compound or composition of Formula I, Formula I-Unsat, Formula I- Sat, Formula II, Formula II-Unsat, Formula II-Sat, Formula III, Formula III-Unsat, Formula
  • the invention embraces a method of treating, reducing, or preventing radiation injury or radiation damage to normal cells in a subject exposed to or at risk of incurring exposure to ionizing radiation comprising administering to said subject prior to, concurrently with, or after the exposure to radiation, a therapeutically effective amount or a prophylactically effective amount of a compound or composition of Formula I, Formula I- Unsat, Formula I-Sat, Formula II, Formula II-Unsat, Formula II-Sat, Formula III, Formula
  • the invention embraces a method of preventing death of radiation-damaged or radiation-injured non-cancerous cells with a therapeutically effective amount or a prophylactically effective amount of a compound or composition of Formula I, Formula I-Unsat, Formula I-Sat, Formula II, Formula Il-Unsat, Formula Il-Sat, Formula III, Formula III-Unsat, Formula Ill-Sat, Formula IV, Formula IV-Unsat, Formula IV-Unsat-R, Formula IV-Unsat-S, Formula IV-Sat-R, Formula IV-Sat-S, Formula V, Formula V-Unsat, Formula V-Sat, Formula VI, Formula Vl-Unsat, Formula VI-Unsat-R, Formula Vl-Unsat-S, Formula Vl-Sat, Formula VI-Sat-R, and Formula Vl-Sat-S, or a hydroquinone of any of those formulas, and tocotrienol quinones, tocot
  • the invention embraces radiotherapy methods for treatment of cancer, comprising administering to a subject a therapeutically effective amount or a prophylactically effective amount of a compound or composition of Formula I, Formula I-Unsat, Formula I-Sat, Formula II, Formula Il-Unsat, Formula Il-Sat, Formula III, Formula
  • the compound, composition, or radioprotective agent is not a prodrug, metabolite, salt, phosphate substituted form, crystalline form, non-crystalline form, isotopologue, deuterated form, hydrate, or solvate thereof.
  • the compound, composition, or radioprotective agent is a salt, a stereoisomer, a mixture of stereoisomers, a hydrate, or solvate thereof.
  • the compound, composition, or radioprotective agent is a stereoisomer or a mixture of stereoisomers thereof.
  • the radiation is selected from the group consisting of radiation exposure from diagnostic X-rays, dental X-rays, radiotherapy for cancer treatment, CT scans (CAT scans), fluoroscopy, mammograms, radionuclide scans, radiation from ingestion of contaminated food or water, radiation from inhalation of contaminated air or gases, and uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills and/or cosmic radiation.
  • the radioprotective agent is selected from one or more compounds of Formula I, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinones form thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinones form thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • prophylactically prior to radiation exposure by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinones form thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula I-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinones form thereof.
  • the radioprotective agent is selected from one or more compounds of Formula I-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula I-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinones form thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • prophylactically prior to radiation exposure by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula II-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula II-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • prophylactically prior to radiation exposure by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula III-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Ill-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Ill-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula Ill-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • the radioprotective agent is selected from one or more compounds of Formula IV-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula IV-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula IV-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • prophylactically prior to radiation exposure by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula V-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula V-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula VI, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula VI, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula VI, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used
  • prophylactically prior to radiation exposure by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Unsat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Unsat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Unsat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Sat, and all stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, salts, phosphate substituted forms, crystalline forms, non-crystalline forms, deuterated forms, hydrates and solvates thereof; or the hydroquinone forms thereof.
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Sat, and all stereoisomers, mixtures of stereoisomers, phosphate substituted forms, and deuterated forms, thereof; or the
  • the radioprotective agent is selected from one or more compounds of Formula Vl-Sat, and all stereoisomers, and mixtures of stereoisomers thereof; or the hydroquinone forms thereof.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof.
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone.
  • the radioprotective agent comprises alpha-tocotrienol quinone.
  • the radioprotective agent comprises beta-tocotrienol quinone.
  • the radioprotective agent comprises gamma-tocotrienol quinone.
  • the radioprotective agent comprises delta- tocotrienol quinone.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the alpha, beta, gamma, and delta-tocotrienol quinones have the naturally- occurring stereochemistry, i.e. 3i?-hydroxy-6E-10E.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocotrienol hydroquinone, beta-tocotrienol hydroquinone, gamma- tocotrienol hydroquinone, and delta-tocotrienol hydroquinone.
  • the radioprotective agent comprises alpha-tocotrienol hydroquinone.
  • the radioprotective agent comprises beta-tocotrienol hydroquinone.
  • the radioprotective agent comprises gamma-tocotrienol hydroquinone.
  • the radioprotective agent comprises delta-tocotrienol hydroquinone.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the alpha, beta, gamma, and delta- tocotrienol hydroquinones have the naturally-occurring stereochemistry, i.e. 3i?-hydroxy-6E- 10E.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocopherol quinone, beta-tocopherol quinone, gamma-tocopherol quinone, and delta-tocopherol quinone.
  • the radioprotective agent comprises alpha-tocopherol quinone.
  • the radioprotective agent comprises beta-tocopherol quinone.
  • the radioprotective agent comprises gamma-tocopherol quinone.
  • the radioprotective agent comprises delta- tocopherol quinone.
  • the one or more compounds are used
  • the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the alpha, beta, gamma, and delta-tocopherol quinones have the naturally- occurring stereochemistry, z ' .e.3(i?)-hydroxy and 7( ?)-methyl and 1 l( ?)-methyl on the tail group.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocopherol hydroquinone, beta-tocopherol hydroquinone, gamma- tocopherol hydroquinone, and delta-tocopherol hydroquinone.
  • the radioprotective agent comprises alpha-tocopherol hydroquinone.
  • the radioprotective agent comprises beta-tocopherol hydroquinone.
  • the radioprotective agent comprises gamma-tocopherol hydroquinone.
  • the radioprotective agent comprises delta-tocopherol hydroquinone.
  • the one or more compounds are used therapeutically during, after, or during and after radiation exposure, by administering a therapeutically effective amount to a subject in need thereof. In another embodiment, the one or more compounds are used prophylactically prior to radiation exposure, by administering a prophylactically effective amount to a subject in need (or potential need) thereof.
  • the alpha, beta, gamma, and delta- tocopherol hydroquinones have the naturally-occurring stereochemistry, i.e. 3( ?)-hydroxy and 7( ?)-methyl and 1 l( ?)-methyl on the tail group.
  • Any one or more of the compounds described herein, including all of the foregoing compounds, can be used in a composition comprising a pharmaceutically acceptable carrier, pharmaceutically acceptable excipient, or pharmaceutically acceptable vehicle. Any one or more of the compounds described herein, including all of the foregoing compounds, can be formulated into a unit dose formulation.
  • any compound, composition, or formulation in the quinone form can also be used in its reduced form (hydroquinone) when desired. That is, the compounds recited herein as cyclohexadienedione compounds (oxidized quinone) form can also be used in their benzenediol (reduced hydroquinone) form as desired.
  • the compounds or compositions can either comprise the listed components or steps, or can “consist essentially of the listed components or steps, or can “consist of the listed components or steps.
  • transitional phrase “comprising” or “comprises” can be replaced by the transitional phrase “consisting essentially of or “consists essentially of.”
  • the transitional phrase “comprising” or “comprises” can be replaced, in some or any embodiments, by the transitional phrase “consisting of or “consists of.”
  • the composition contains the components listed, and may contain other components which do not substantially affect the condition being treated, but do not contain any other components which substantially affect the condition being treated other than those components expressly listed; or, if the composition does contain extra components other than those listed which substantially affect the condition being treated, the composition does not contain a sufficient concentration or amount of the extra components to substantially affect the condition being treated.
  • composition when a method is described as "consisting essentially of the listed steps, the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed.
  • the composition when a composition is described as 'consisting essentially of a component, the composition may additionally contain any amount of pharmaceutically acceptable carriers, vehicles, excipients, or diluents and other such components which do not substantially affect the condition being treated.
  • Figures 1 A and B show the percent survival and mean weight change, respectively, for CD2F1 mice exposed to LD 90 dose of total body irradiation and treated with (3R)-alpha-tocotrienol quinone or vehicle only.
  • Figures 2 A and B show the percent survival and mean weight change, respectively, for CD2F1 mice exposed to LD100 dose of total body irradiation and treated with (3R)-alpha-tocotrienol quinone or vehicle only.
  • Figure 3 shows the injection sites after 28 days for mice treated with (3R)-alpha- tocotrienol quinone ( Figure 3 A) and delta-tocotrienol ( Figures 3 B-E), respectively.
  • the present invention provides compounds and compositions for use in treating or protecting against injury or damage caused by radiation exposure, and methods of using such compounds for treating or for protecting against injury or damage caused by radiation exposure.
  • the abbreviations used herein have their conventional meaning within the chemical and biological arts, unless otherwise specified.
  • Reference to "about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to "about X” includes description of "X”.
  • subject an individual organism, preferably a vertebrate, more preferably a mammal, most preferably a human.
  • radiation is meant radiation, including ionizing radiation, capable of causing molecular or cellular damage.
  • forms of radiation include ultraviolet radiation, alpha radiation, beta radiation, x-rays, and gamma rays.
  • Sources of radiation include, in some embodiments, radioactive isotopes, which may be naturally-occurring or man-made, and cosmic rays. Radiation can be emitted due to the gradual decay of radioactive isotopes, or due to nuclear fission or fusion events (as in an atomic bomb or nuclear reactor).
  • the radiation is x-ray radiation.
  • the radiation is gamma radiation.
  • the radiation is beta radiation.
  • the radiation is alpha radiation.
  • the radiation is ultraviolet radiation.
  • the radiation is radiation due to radiation therapy.
  • the radiation is radiation due to radioactive fallout or contamination.
  • the term "preventing radiation damage” means eliminating, ameliorating or decreasing one or more indicia of radiation damage in a cell, tissue, or subject that has received one or more compounds or compositions disclosed herein, compared to a cell, tissue, or subject that has not received one or more compounds or compositions disclosed herein.
  • the term “protecting a cell, tissue, or subject against radiation damage” means eliminating, ameliorating or decreasing one or more indicia of radiation damage in the cell, tissue, or subject which has received one or more compounds or compositions disclosed herein, compared to a cell, tissue, or subject which has not received one or more compounds or compositions disclosed herein.
  • treatment or prophylaxis of radiation damage in a cell, tissue, or subject involves decreasing damage to one or more nucleic acid molecules in a cell, tissue, or subject which has received one or more compounds or compositions disclosed herein by at least about 10%, 20%, 30%>, 40%>, 50%, 80%, 90%), or 95%, compared to a cell, tissue, or subject which has not received one or more compounds or compositions disclosed herein.
  • Treating" radiation exposure with the compounds and methods discussed herein is defined as administering one or more of the compounds discussed herein, with or without additional therapeutic agents, in order to reduce or eliminate either the deleterious effects of radiation exposure or one or more symptoms of radiation exposure, or to retard the progression of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to reduce the severity of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to suppress the clinical manifestation of radiation exposure, or to suppress the manifestation of adverse symptoms of radiation exposure.
  • “Prophylaxis” against injury or damage caused by radiation exposure with the compounds and methods discussed herein is defined as administering one or more of the compounds discussed herein, with or without additional therapeutic agents, prior to exposure to radiation, in order to reduce or eliminate either the deleterious effects of radiation exposure or one or more symptoms of radiation exposure, or to retard the progression of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to reduce the severity of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to suppress the clinical manifestation of radiation exposure, or to suppress the manifestation of adverse symptoms of radiation exposure.
  • Prophylactic use of the compounds and methods of the invention would include, in some embodiments, administering one or more of the compounds described herein to patients undergoing radiotherapy at risk of radiation damage or injury, where the compound or compounds are administered prior to radiotherapy, or to workers in the nuclear industry at risk of exposure to radiation prior to the arrival of the workers at a site where they could be exposed to excessive radiation.
  • “Therapeutic use” of the compounds discussed herein is defined as using one or more of the compounds discussed herein to treat radiation exposure.
  • “Prophylactic use” of the compounds discussed herein is defined as using one or more of the compounds discussed herein as a prophylaxis against radiation exposure (e.g. to suppress the deleterious effects of radiation exposure or one or more symptoms of radiation exposure) prior to radiation exposure.
  • a “therapeutically effective amount” of a compound is an amount of the compound, which, when administered to a subject, is sufficient to reduce or eliminate either the deleterious effects of radiation exposure or one or more symptoms of radiation exposure, or to retard the progression of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to reduce the severity of the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure, or to suppress the deleterious effects of radiation exposure or of one or more symptoms of radiation exposure.
  • a “prophylactically effective amount” of a compound is an amount of the compound, which, when administered to a subject prior to radiation exposure, is sufficient to suppress the deleterious effects of radiation exposure, or the clinical manifestation of radiation exposure, or to suppress the manifestation of adverse symptoms of radiation exposure.
  • therapeutically effective amount or a prophylactically effective amount can be given in one or more administrations.
  • a "radioprotective agent” is a compound suitable for therapeutic use for radiation exposure, or suitable for prophylactic use against radiation exposure.
  • the radioprotective agent is one or more compounds or compositions of Formula I, Formula I-Unsat, Formula I-Sat, Formula II, Formula II-Unsat, Formula II-Sat, Formula III, Formula III-Unsat, Formula Ill-Sat, Formula IV, Formula IV-Unsat, Formula IV-Unsat-R, Formula IV-Unsat-S, Formula IV-Sat, Formula IV-Sat-R, Formula IV-Sat-S, Formula V, Formula V-Unsat, Formula V-Sat, Formula VI, Formula Vl-Unsat, Formula VI- Unsat-R, Formula Vl-Unsat-S, Formula Vl-Sat, Formula VI-Sat-R, and Formula Vl-Sat-S, or a hydroquinone of any of those formulas, and tocotrienol quinones, tocotrienol
  • a subject in "potential need" of a compound, composition, or formulation of the invention, or a method of the invention is a subject who may be exposed to excessive radiation, in some embodiments, who has a about a 0.001% chance, about a 0.01% chance, about a 0.1% chance, about a 1% chance, about a 5% chance, about a 10% chance, about a 25%o chance, or about a 50%> chance of being exposed to excessive radiation, or at least about a 0.001% chance, at least about a 0.01% chance, at least about a 0.1% chance, at least about a 1% chance, at least about a 5% chance, at least about a 10% chance, at least about a 25% chance, or at least about a 50% chance of being exposed to excessive radiation.
  • excessive radiation can be more than about 1 mSv in one year, more than about 2 mSv in one year, more than about 5 mSv in one year, more than about 10 mSv in one year, more than about 20 mSv in one year, or more than about 50 mSv in one year. In some embodiments, excessive radiation can be more than about 1 mGray in one year, more than about 2 mGray in one year, more than about 5 mGray in one year, more than about 10 mGray in one year, more than about 20 mGray in one year, or more than about 50 mGray in one year.
  • a subject in need or potential need of a compound, composition, or formulation of the invention, or a method of the invention can also be a subject who desires protection against exposure to routine radiation, such as natural background radiation, such as ultraviolet light, in order to minimize the effects of routine or background exposure to radiation.
  • routine radiation such as natural background radiation, such as ultraviolet light
  • Compounds for use in the invention include one or more compounds of Formula I:
  • each bond indicated with a dashed line independently of the other bonds indicated with a dashed line, can be a single bond or a double bond;
  • R 1 , R2 , and R 3 are independently selected from H, (Ci-C 4 )-alkyl, (Ci-C 4 )-haloalkyl, -CN, -F, -CI, -Br, and -I; and
  • R 4 and R 5 are independently selected from hydroxy and (Ci-C 4 )-alkyl, and R 6 is hydrogen; or R 4 is (Ci-C 4 )-alkyl, and R 5 and R 6 are hydrogen; or
  • R 4 is (Ci-C 4 )-alkyl, and R 5 and R 6 together form the second bond of a double bond between the carbon atoms to which they are attached; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, non-crystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula I-Unsat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula I-Sat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula II:
  • Compounds for use in the invention also include one or more compounds of Formula II-Unsat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula II- Sat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula III:
  • Compounds for use in the invention also include one or more compounds of Formula III-Unsat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula III- Sat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • Compounds for use in the invention also include one or more compounds of Formula IV:
  • the compounds of Formula IV are compounds of Formula I -R:
  • the compounds of Formula IV are compounds of Formula IV-S:
  • Compounds for use in the invention also include one or more compounds of Formula IV-Unsat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • the compounds of Formula IV- Unsat are compounds of Formula IV-Unsat-R:
  • the compounds of Formula IV-Unsat are compounds of Formula IV-
  • Compounds for use in the invention also include one or more compounds of Formula IV-Sat:
  • substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • the compounds of Formula IV-Sat are compounds of Formula IV-Sat-R:
  • the compounds of Formula IV-Sat are compounds of Formula IV-Sat- S:
  • Compounds for use in the invention also include one or more compounds of
  • bonds and substituents are as indicated for Formula I; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • the compounds of Formula V are compounds of Formula V-R:
  • Compounds for use in the invention also include one or more compounds of Formula V-Unsat:
  • the compound of Formula V-Unsat is 3R-alpha-tocotrienol quinone. In some embodiments, the compound of Formula V-Unsat is 3S-alpha-tocotrienol quinone.
  • Compounds for use in the invention also include one or more compounds of Formula V-Sat:
  • the compound of Formula V-Sat is (3R,7R,1 lR)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3S,7R,1 lR)-alpha- tocopherol quinone.
  • the compound of Formula V-Sat is (3R,7S,11R)- alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3S,7S,1 lR)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V- Sat is (3R,7R,11 S)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3S,7R,11 S)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3R,7S,11 S)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3R,7S,11 S)-alpha-tocopherol quinone. In some embodiments, the compound of Formula V-Sat is (3R,7S,11 S)-alpha-tocopherol quinone. In some embodiments,
  • the compound of Formula V-Sat is (3S,7S,11 S)-alpha-tocopherol quinone.
  • Compounds for use in the invention also include one or more compounds of Formula VI:
  • R , R , and R 1J are independently selected from the group consisting of -CH 3 and -H; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, non-crystalline form, isotopologue, deuterated form, hydrate, or solvate thereof; or the hydroquinone form thereof.
  • the compounds of Formula VI are compounds of Formula VI-R:
  • Formula VI are compounds of Formula VI-S:
  • Compounds for use in the invention also include one or more compounds of Formula Vl-Unsat:
  • the substituents are as indicated for formula VI; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, crystalline form, isotopologue, deuterated form, hydrate, or solvate thereof; or the hydroquinone form thereof.
  • the compounds of Formula VI- Unsat are com ounds of Formula VI-Unsat-R:
  • Vl-Unsat-S are compounds of Formula Vl-Unsat-S:
  • Compounds for use in the invention also include one or more compounds of Formula Vl-Sat:
  • substituents are as indicated for formula VI; or a stereoisomer, mixtures of stereoisomers, prodrug, metabolite, salt, phosphate substituted form, crystalline form, noncrystalline form, isotopologue, deuterated form, hydrate, or solvate thereof;
  • the compounds of Formula Vl-Sat are com ounds of Formula VI-Sat-R:
  • Vl-Sat-S are compounds of Formula Vl-Sat-S:
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocotrienol quinone, beta- tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone.
  • the radioprotective agent comprises alpha-tocotrienol quinone.
  • the radioprotective agent comprises beta-tocotrienol quinone.
  • the radioprotective agent comprises gamma-tocotrienol quinone.
  • the radioprotective agent comprises delta-tocotrienol quinone.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocotrienol hydroquinone, beta-tocotrienol hydroquinone, gamma-tocotrienol hydroquinone, and delta-tocotrienol hydroquinone.
  • the radioprotective agent comprises alpha-tocotrienol hydroquinone.
  • the radioprotective agent comprises beta-tocotrienol hydroquinone.
  • the radioprotective agent comprises gamma-tocotrienol hydroquinone.
  • the radioprotective agent comprises delta-tocotrienol hydroquinone.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocopherol quinone, beta- tocopherol quinone, gamma-tocopherol quinone, and delta-tocopherol quinone.
  • the radioprotective agent comprises alpha-tocopherol quinone.
  • the radioprotective agent comprises beta-tocopherol quinone.
  • the radioprotective agent comprises gamma-tocopherol quinone.
  • the radioprotective agent comprises delta-tocopherol quinone.
  • the radioprotective agent comprises one or more compounds selected from the group consisting of alpha-tocopherol hydroquinone, beta-tocopherol hydroquinone, gamma-tocopherol hydroquinone, and delta-tocopherol hydroquinone.
  • the radioprotective agent comprises alpha-tocopherol hydroquinone.
  • the radioprotective agent comprises beta-tocopherol hydroquinone.
  • the radioprotective agent comprises gamma-tocopherol hydroquinone.
  • the radioprotective agent comprises delta-tocopherol hydroquinone.
  • any composition in the quinone form can also be used in its reduced form (hydroquinone) when desired. That is, the compounds recited herein as cyclohexadienedione compounds (oxidized quinone) form can also be used in their benzenediol (reduced hydroquinone) form as desired.
  • the salts of the compounds comprise pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts are those salts which can be administered as drugs or pharmaceuticals to humans and/or animals and which, upon administration, retain at least some of the biological activity of the free compound (neutral compound or non-salt compound).
  • the desired salt of a basic compound may be prepared by methods known to those of skill in the art by treating the compound with an acid.
  • inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid.
  • organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acids, and salicylic acid. Salts of basic compounds with amino acids, such as aspartate salts and glutamate salts, can also be prepared.
  • inorganic salts of acid compounds include, but are not limited to, alkali metal and alkaline earth salts, such as sodium salts, potassium salts, magnesium salts, and calcium salts;
  • organic salts of acid compounds include, but are not limited to, procaine, dibenzylamine, N-ethylpiperidine, N,N- dibenzylethylenediamine, and triethylamine salts. Salts of acidic compounds with amino acids, such as lysine salts, can also be prepared.
  • the invention also includes all stereoisomers of the compounds, including diastereomers and enantiomers.
  • the invention also includes mixtures of stereoisomers in any ratio, including, but not limited to, racemic mixtures.
  • stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted. If stereochemistry is explicitly indicated for one portion or portions of a molecule, but not for another portion or portions of a molecule, the structure is intended to embrace all possible stereoisomers for the portion or portions where stereochemistry is not explicitly indicated.
  • the compounds can be administered in prodrug form.
  • Prodrugs are derivatives of the compounds, which are themselves relatively inactive but which convert into the active compound when introduced into the subject in which they are used by a chemical or biological process in vivo, such as an enzymatic conversion.
  • Suitable prodrug formulations include, but are not limited to, peptide conjugates of the compounds of the invention and esters of compounds of the inventions. Further discussion of suitable prodrugs is provided in H. Bundgaard, Design of Prodrugs, New York: Elsevier, 1985; in R. Silverman, The Organic Chemistry of Drug Design and Drug Action, Boston: Elsevier, 2004; in R.L.
  • Metabolites of the compounds are also embraced by the invention.
  • C1-C4 alkyl is intended to embrace a saturated linear, branched, cyclic, or a combination thereof, hydrocarbon of 1 to 4 carbon atoms.
  • C 1 -C 4 alkyl are methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, cyclopropyl-methyl, and methyl-cyclopropyl.
  • Halogen or "halo” designates fluoro, chloro, bromo, and iodo.
  • C1-C4 haloalkyl is intended to embrace any C 1 -C 4 alkyl substituent having at least one halogen substituent, in some embodiments 1 to 6 halogens, in some embodiments, 1 to 3 halogens; the halogen can be attached via any valence on the C1-C4 alkyl group.
  • C1-C4 haloalkyl is -CF 3 , -CC1 3 , -CHF 2 , -CHC1 2 , -CHBr 2 , -CH 2 F, -CH 2 C1.
  • Deuterated form means the compound is isotopically enriched for deuterium in at least one atom.
  • isotopologue means a compound which differs, i.e. in the number of neutrons, in its isotopic composition of at least one atom from the parent molecule having a natural isotopic composition. In some or any embodiments, the compound is isotopically enriched.
  • isotopic composition refers to the amount of each isotope present for a given atom
  • naturally occurring isotopic composition refers to the naturally occurring isotopic composition or abundance for a given atom.
  • Atoms containing their natural isotopic composition may also be referred to herein as "non-enriched" atoms.
  • the atoms of the compounds recited herein are meant to represent any stable isotope of that atom.
  • FT or hydrogen the position is understood to have hydrogen at its natural isotopic composition.
  • isotopic enriched refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom's natural isotopic abundance.
  • deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%.
  • the isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
  • isotopically enriched refers to an atom having an isotopic composition other than the natural isotopic composition of that atom.
  • isotopically enriched may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.
  • Phosphate substituted form means that any unsubstituted hydroxy group of the compound is substituted with a phosphate group, -P(0)(OH)2 or -PO 3 " .
  • the compounds, compositions, and methods of the invention can be used in any situation where protection against radiation is desired, whether exposure to such radiation is known to be certain to occur (in some embodiments, a patient undergoing a CT scan) or exposure to radiation is possible (in some embodiments, a worker in a nuclear power plant).
  • the compounds, compositions, and methods of the invention can be used to protect against radiation exposure from, in some embodiments, diagnostic X-rays, dental X-rays,
  • radiotherapy for cancer treatment CT scans (CAT scans), fluoroscopy, mammograms, radionuclide scans, radiation from ingestion of contaminated food or water, radiation from inhalation of contaminated air or gases, and uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills and/or cosmic radiation.
  • CT scans CAT scans
  • fluoroscopy fluoroscopy
  • mammograms radionuclide scans
  • radiation from ingestion of contaminated food or water radiation from inhalation of contaminated air or gases
  • uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills and/or cosmic radiation uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills and/or cosmic radiation.
  • ultraviolet light such as from prolonged exposure to sunlight, or exposure to intense sunlight.
  • Subjects who are exposed to radiation include, in some embodiments, patients undergoing diagnostic or therapeutic radiation exposure, such as occurs during medical or dental procedures, such as radiography, fluoroscopy, dental X-rays, and CT scans, and therapeutic radiation treatment.
  • Subjects who are exposed to radiation also include persons who routinely work at high elevation, such as aircraft flight crew members, or who spend a prolonged period at high elevation (greater than about 1 mile or about 1.6 kilometers above sea level), such as mountain climbers, or who travel into outer space, such as astronauts and space tourists.
  • Subjects who are exposed to radiation also include persons who must decontaminate sites which are contaminated with radioactive waste, or with waste containing a high amount of radioactivity such as coal ash, or miners who work in sites with elevated radioactivity.
  • Subjects who are at risk of being exposed to radiation include persons who routinely work with or near radiation or radioactive materials, such as X-ray technicians, nuclear medicine specialists, nuclear power plant workers, and persons who live near a nuclear power plant.
  • the compounds, compositions, and methods are used to protect against excess radiation; that is, radiation in excess of the natural background radiation.
  • the 2007 recommendation of the International Commission on Radiological Protection (ICRP) for exposure of the general public to radiation is a limit of 1 milliSievert (1 mSv) per year (Wrixon, A.D., J. Radiol. Prot. 28: 161-168 (2008)).
  • ICRP International Commission on Radiological Protection
  • the compounds, compositions, and methods can be used for therapeutic or prophylactic use in subjects whose expected or actual dose of radiation exceeds about 1 mSv in one year.
  • the recommended occupational exposure from the ICRP is 20 mSv per year, averaged over five years, with no more than 50 mSv exposure in any one year, and thus, the compounds, compositions, and methods can be used for therapeutic or prophylactic use in subjects whose expected or actual dose of radiation exceeds that level.
  • the compounds, compositions, and methods can be used for therapeutic or prophylactic use in subjects whose expected or actual dose of radiation exceeds about 2 mSv in one year, about 5 mSv in one year, about 10 mSv in one year, about 20 mSv in one year, or about 50 mSv in one year.
  • the compounds, compositions, and methods can be used for therapeutic or prophylactic use in subjects whose expected or actual dose of radiation exceeds about 2 mGray in one year, about 5 mGray in one year, about 10 mGray in one year, about 20 mGray in one year, or about 50 mGray in one year.
  • the compounds, compositions, and methods can be used for therapeutic or prophylactic use in subjects who wish to minimize the effects of exposure to routine or background radiation, such as, in some embodiments, routine or everyday exposure to ultraviolet light.
  • the compounds, compositions, and methods are used to protect against exposure to extreme amounts of radiation, in some embodiments, radiation at or greater than about the LDio, LD 2 o, LD 50 , or LDso dose for an organism (where LD is the lethal dose). Exposure to such high amounts of radiation can occur, in some embodiments, due to accidents at nuclear power plants, or accidents in handling extremely radioactive substances such as enriched uranium-235 or plutonium, or by proximity to a nuclear explosion or a bomb designed to spread lethal amounts of radioactivity.
  • the compounds, compositions, and methods are used to protect against exposure to radiation which damages the skin.
  • radiation includes, in some embodiments, ultraviolet radiation.
  • Topical administration of the compounds and compositions as disclosed herein may be used for such protection (in some embodiments, in a lotion, cream, salve, or spray), as well as other routes of administration described below.
  • the compounds, compositions, and methods are used to protect against exposure to radiation which damages the eyes.
  • radiation includes, in some embodiments, ultraviolet radiation.
  • Topical administration of the compounds and compositions as disclosed herein may be used for such protection (in some embodiments, in eyedrops), as well as other routes of administration described below.
  • the utility of the compounds, compositions, and methods of the present invention for radioprotection may be demonstrated both in vitro and in vivo.
  • the ability of cultured cells to form clones (colonies) may be evaluated as a function of exposure to radiation, such as X-rays. Cells are either not treated or are treated with a compound or composition of the invention at a certain time (in some embodiments, 30 minutes) prior to exposure.
  • the degree of retention of ability to form clones after exposure, in comparison to untreated cells is directly related to the protective effect of the drug.
  • a typical experiment of this type may be carried out essentially as described by Snyder and Lachmann Radiation Res. (1989) 120: 121-128.
  • the utility of the compounds, compositions, and methods of the present invention for radioprotection can be evaluated by measuring the production of DNA strand breaks upon exposure to radiation, such as X-rays.
  • Cells are either not treated or are treated with a compound or composition of the invention at a certain time (in some embodiments, 30 minutes) prior to exposure.
  • the extent of DNA strand breakage after exposure, in comparison to that in untreated cells, is inversely related to the protective effect of the drug.
  • a typical experiment of this type may be carried out essentially as described by Snyder Int. J. Radiat. Biol. (1989) 55:773.
  • the utility of the compounds, compositions, and methods of the present invention for radioprotection may be evaluated by the survivability of mice exposed to whole body irradiation.
  • Animals, either pre-dosed with a compound or composition disclosed herein, or not dosed (i.e., control animals), are exposed to whole body irradiation (such as, in some embodiments, 1500 rads).
  • Control animals are expected to survive about 12-15 days.
  • the degree of survivability of the dosed animals, in comparison to the controls, is directly related to the protective effect of the compound or composition administered. A typical experiment of this type may be carried out essentially as described by Carroll et al. J. Med. Chem. (1990) 33:2501.
  • the production of DNA strand breaks in lymphocytes taken from treated animals exposed to whole body irradiation may be evaluated in comparison to untreated control animals.
  • the viability and clonogenicity of bone marrow cells taken from treated animals exposed to whole body irradiation may be evaluated in
  • compositions by formulation with additives such as pharmaceutically acceptable excipients, pharmaceutically acceptable carriers, and pharmaceutically acceptable vehicles.
  • suitable pharmaceutically acceptable excipients, carriers and vehicles include processing agents and drug delivery modifiers and enhancers, such as, in some embodiments, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl- -cyclodextrin, polyvinylpyrrolidone, low melting waxes, ion exchange resins, and the like, as well as combinations of any two or more thereof.
  • Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences,” Mack Pub. Co., New Jersey (1991), and “Remington: The Science and Practice of Pharmacy,” Lippincott Williams & Wilkins, Philadelphia, 20th edition (2003) and 21st edition (2005), incorporated herein by reference.
  • a pharmaceutical composition can comprise a unit dose formulation, where the unit dose is a dose sufficient to have a therapeutic or prophylactic effect.
  • compositions containing the compounds of the invention may be in any form suitable for the intended method of administration, including, in some embodiments, a solution, a suspension, or an emulsion.
  • Liquid carriers are typically used in preparing solutions, suspensions, and emulsions.
  • Liquid carriers contemplated for use in the practice of the present invention include, in some embodiments, water, saline,
  • the liquid carrier may contain other suitable pharmaceutically acceptable additives such as solubilizers, emulsifiers, nutrients, buffers, preservatives, suspending agents, thickening agents, viscosity regulators, stabilizers, and the like.
  • suitable organic solvents include, in some embodiments, monohydric alcohols, such as ethanol, and polyhydric alcohols, such as glycols.
  • Suitable oils include, in some embodiments, sesame oil, soybean oil, coconut oil, olive oil, safflower oil, cottonseed oil, and the like.
  • the carrier can also be an oily ester such as ethyl oleate, isopropyl myristate, and the like.
  • Compositions of the present invention may also be in the form of microparticles, microcapsules, liposomal encapsulates, and the like, as well as combinations of any two or more thereof.
  • Time-release or controlled release delivery systems may be used, such as a diffusion controlled matrix system or an erodible system, as described for example in: Lee, "Diffusion-Controlled Matrix Systems", pp. 155-198 and Ron and Langer, "Erodible
  • the matrix may be, in some embodiments, a biodegradable material that can degrade spontaneously in situ and in vivo, in some embodiments, by hydrolysis or enzymatic cleavage, e.g., by proteases.
  • the delivery system may be, in some embodiments, a naturally occurring or synthetic polymer or copolymer, in some
  • Exemplary polymers with cleavable linkages include polyesters, polyorthoesters, polyanhydrides, polysaccharides, poly(phosphoesters), polyamides, polyurethanes, poly(imidocarbonates) and poly(phosphazenes).
  • the compounds of the invention may be administered enterally, orally, parenterally, sublingually, by inhalation (e.g. as mists or sprays), rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
  • suitable modes of administration include oral, subcutaneous, transdermal, transmucosal, iontophoretic, intravenous, intraarterial, intramuscular, intraperitoneal, intranasal (e.g. via nasal mucosa), subdural, rectal, gastrointestinal, and the like, and directly to a specific or affected organ or tissue.
  • Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, and intrasternal injection or infusion techniques. The compounds are mixed with
  • Oral administration is a preferred route of administration, and
  • formulations suitable for oral administration are preferred formulations.
  • the compounds described for use herein can be administered in solid form, in liquid form, in aerosol form, or in the form of tablets, pills, powder mixtures, capsules, granules, injectables, creams, solutions, suppositories, enemas, colonic irrigations, emulsions, dispersions, food premixes, and in other suitable forms.
  • the compounds can also be administered in liposome formulations.
  • the compounds can also be administered as prodrugs, where the prodrug undergoes transformation in the treated subject to a form which is therapeutically effective. Additional methods of administration are known in the art.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, in some embodiments, as a solution in propylene glycol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch.
  • Such dosage forms may also comprise additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
  • Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents.
  • the compounds of the present invention can also be administered in the form of liposomes.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.
  • the preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.W., p. 33 et seq. (1976).
  • formulations of the present invention may comprise two or more compounds or compositions as described herein.
  • kits containing materials useful for treatment or prophylaxis of radiation exposure.
  • the invention also provides kits comprising any one or more of the compounds of the invention.
  • the kits may be used for any of the methods described herein, including, in some embodiments, for treatment of or prophylaxis against radiation exposure in a subject.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host to which the active ingredient is administered and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, body area, body mass index (BMI), general health, sex, and diet of the patient; time of administration, route of administration, rate of excretion, or drug combination; and the type, progression, and severity of the particular disease undergoing therapy.
  • BMI body mass index
  • pharmaceutical unit dosage chosen is usually fabricated and administered to provide a defined final concentration of drug in the blood, tissues, organs, or other targeted region of the body.
  • the therapeutically effective amount or prophylactically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician.
  • the single or multiple dosages which can be used include an amount independently selected from about 0.1 mg/kg to about 600 mg/kg body weight, or about 1.0 mg/kg to about 500 mg/kg body weight, or about 1.0 mg/kg to about 400 mg/kg body weight, or about 1.0 mg/kg to about 300 mg/kg body weight, or about 1.0 mg/kg to about 200 mg/kg body weight, or about 1.0 mg/kg to about 100 mg/kg body weight, or about 1.0 mg/kg to about 50 mg/kg body weight, or about 1.0 mg/kg to about 30 mg/kg body weight, or about 1.0 mg/kg to about 10 mg/kg body weight, or about 10 mg/kg to about 600 mg/kg body weight, or about 10 mg/kg to about 500 mg/kg body weight, or about 10 mg/kg to about 400 mg/kg body weight, or about 10 mg/kg to about 300 mg/kg body weight, or about 10 mg/kg to about 200 mg/kg body weight, or about 10 mg/kg to about 100 mg/kg body weight, or about
  • Single or multiple doses can be administered.
  • the dose is administered once, twice, three times, four times, five times, or six times.
  • the dose is administered once per day, twice per day, three times per day, or four times per day.
  • the dose is administered every hour, every two hours, every three hours, every four hours, every 6 hours, every 12 hours, or every 24 hours.
  • Single or multiple doses can be administered during or after radiation exposure.
  • the dose is administered once, twice, three times, four times, five times, or six times during or after radiation exposure.
  • the dose is administered once per day, twice per day, three times per day, or four times per day during or after radiation exposure.
  • the dose is administered every hour, every two hours, every three hours, every four hours, every 6 hours, every 12 hours, or every 24 hours during or after radiation exposure.
  • Single or multiple doses can be administered before radiation exposure.
  • the dose is administered once, twice, three times, four times, five times, or six times before radiation exposure.
  • the dose is administered once per day, twice per day, three times per day, or four times per day before radiation exposure.
  • the dose is administered every hour, every two hours, every three hours, every four hours, every 6 hours, every 12 hours, or every 24 hours before radiation exposure.
  • the dose is administered about 30 minutes before radiation exposure, about 1 hour before radiation exposure, about 2 hours before radiation exposure, about 3 hours before radiation exposure, about 4 hours before radiation exposure, about 6 hours before radiation exposure, about 8 hours before radiation exposure, about 10 hours before radiation exposure, about 12 hours before radiation exposure, and/or about 24 hours before radiation exposure. In some embodiments, the dose is administered about 4 hours before radiation exposure. In some embodiments, the dose is administered about 24 hours before radiation exposure. In some embodiments, the dose is administered about 4 hours and about 24 hours before radiation exposure.
  • the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents used in the treatment of or prophylaxis against radiation exposure.
  • the compound(s) of the invention are administered as the sole active pharmaceutical agent that is present in a therapeutically effective amount.
  • the additional active agents may generally be employed in therapeutic amounts as indicated in the Physicians' Desk Reference (PDR) 53rd Edition (1999), or such therapeutically useful amounts as would be known to one of ordinary skill in the art.
  • the compounds of the invention and the other therapeutically active agents or prophylactically effective agents can be administered at the recommended maximum clinical dosage or at lower doses. Dosage levels of the active compounds in the compositions of the invention may be varied so as to obtain a desired response depending on the route of administration, severity of the radiation exposure and the response of the patient.
  • the therapeutic agents or prophylactic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents or prophylactic agents can be given as a single composition.
  • the one or more radioprotective agent can be administered during radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 48 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 24 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 12 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 4 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 1 hour after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 30 minutes after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 15 minutes after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 24 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0
  • radioprotective agent can be administered about 0 to about 10 minutes after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 5 minutes after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 48 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 24 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 12 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 4 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 2 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 1 hour after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 48 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 24 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 12 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 4 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 2 hours after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 1 hour after radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, bout 16 hours, about 17 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, and/or about 48 hours after radiation exposure.
  • the one or more radioprotective agent can be administered about 0 to about 48 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 24 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 12 hours before radiation exposure in single or multiple doses.
  • radioprotective agent can be administered about 0 to about 4 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 1 hour before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 30 minutes before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 15 minutes before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 10 minutes before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 4 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 1 hour before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 30 minutes before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 0 to about 15 minutes
  • radioprotective agent can be administered about 0 to about 5 minutes before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 48 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 24 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 12 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 4 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 2 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes to about 1 hour before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 48 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 24 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 12 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 4 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 2 hours before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 30 minutes to about 1 hour before radiation exposure in single or multiple doses.
  • the one or more radioprotective agent can be administered about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, bout 16 hours, about 17 hours, about 18 hours, about 20 hours, about 22 hours, about 24 hours, about 30 hours, about 36 hours, about 42 hours, and/or about 48 hours before radiation exposure.
  • the compounds of this invention can be prepared from readily available starting materials using general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • Patent Application Publications No. 2006/0281809 and 2010/0105930 are examples of Patent Application Publications No. 2006/0281809 and 2010/0105930.
  • the compounds of this invention will typically contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer- enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this invention, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, in some embodiments, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, in some embodiments, chiral column chromatography, chiral resolving agents and the like. [0122] The invention is further described by the following non-limiting examples and embodiments.
  • TBI total body irradiation
  • mice Male CD2F1 mice (Charles River Laboratories), aged 6-8 weeks, were randomly and prospectively assigned to receive treatment with either a test compound or vehicle only. On Day 0, the animals were placed in a pie cage and exposed to total body irradiation (TBI) with a dose of 8.75 Gy or 9.75 Gy to achieve an approximate LD 5 o or LDgo survival outcome, respectively; these doses resulted in LD 90 and LDioo values in the actual experiment. Treatments were administered at 24 hours and 4 hours prior to irradiation.
  • TBI total body irradiation
  • mice were housed in disposable cages with sterile wood chip bedding, food, and water. The mice were acclimated for at least 3 days and given food and tap water ad libitum. The animals were examined prior to initiation of the study to assure adequate health and suitability. Animals that were found to be diseased or unsuitable were not assigned to the study.
  • TBI Total Body Irradiation
  • mice were placed in a pie cage in groups of 9-11 at a time. Radiation was generated with a 160 kilovolt potential (18-ma) source at a focal distance of 25 cm, hardened with a 0.35 mm Al filtration system. The animals were subjected to TBI at a rate of ⁇ 100 cGy. Dosimetry (Fluke 3504 dosimeter with farmer type 0.6 cm ion chamber probe) was used with each radiation to ensure that all animals received the correct dose.
  • Test compound was dissolved in PEG-400/2%> Tween 80 and mixed until visually homogeneous at a concentration of 90 mg/mL. All compound solutions were stored at room temperature, protected from light, and used within 24 hours of preparation.
  • SC body weight dose(s) of the test compound formulation or vehicle only formulation as described herein. All animals were dosed at approximately the same time on the dosing day ( ⁇ 1 hour). Subcutaneous doses were administered via bolus injection between the skin and underlying layers of tissue in the scapular region on the back of each animal. The hair was not clipped from the injection site prior to dosing. The injection site was monitored for necrosis and other changes to the skin and hair.
  • Figures 1 and 2 show the percent survival and body weight for test compound alpha-tocotrienol quinone compared to vehicle only at LD90 and LD100 radiation doses, respectively.
  • Figure 3 shows the injection sites after 28 days for mice treated with test compounds alpha-tocotrienol quinone (Figure 3A) and delta-tocotrienol ( Figures 3B-E), respectively.
  • the injection site for mice treated with delta-tocotrienol exhibited necrosis and hair loss, whereas necrosis and hair loss were not observed at the injection site for mice treated with alpha-tocotrienol quinone.
  • mice are randomly and prospectively assigned to receive treatment with either a test compound or vehicle only.
  • the animals are exposed to gamma-radiation with a dose sufficient to achieve survival outcome between LD 2 o to LDgo- Treatments are administered at set time points between 48 hours and 1 hour prior to irradiation. Animals are monitored for survival twice daily, and those that lose greater than 30% of their total starting body weight are euthanized and counted as having died on that day. Animals are also monitored for various symptoms of radiation damage.
  • Test compound is dissolved in PEG-400/2% Tween 80 and mixed until visually homogeneous at a concentration of 90 mg/mL. All compound solutions are stored at room temperature, protected from light, and used within 24 hours of preparation.
  • the animals are each administered with single or multiple subcutaneous (SC)
  • Compounds are evaluated for their ability to increase survival rates and/or reduce or prevent symptoms of radiation damage.
  • mice are randomly and prospectively assigned to receive treatment with either a test compound or vehicle only.
  • the animals are exposed to ultraviolet radiation (UVA and/or UVB) with doses sufficient to achieve an LD 2 o to LDso survival outcome.
  • UVA and/or UVB ultraviolet radiation
  • Treatments are administered at set time points between 48 hours and 1 hour prior to irradiation. Animals are monitored for survival twice daily, and those that lose greater than 30% of their total starting body weight are euthanized and counted as having died on that day. Animals are also monitored for various symptoms of radiation damage.
  • Test compound is dissolved in PEG-400/2% Tween 80 and mixed until visually homogeneous at a concentration of 90 mg/mL. All compound solutions are stored at room temperature, protected from light, and used within 24 hours of preparation.
  • the animals are each administered with single or multiple subcutaneous (SC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes pour le traitement ou la prophylaxie d'une exposition à des rayonnements.
PCT/US2015/063824 2015-01-12 2015-12-03 Quinones pour la protection contre une exposition à des rayonnements Ceased WO2016114860A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017536942A JP2018502127A (ja) 2015-01-12 2015-12-03 放射線被曝に対する防護のためのキノン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562102541P 2015-01-12 2015-01-12
US62/102,541 2015-01-12

Publications (1)

Publication Number Publication Date
WO2016114860A1 true WO2016114860A1 (fr) 2016-07-21

Family

ID=55069084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/063824 Ceased WO2016114860A1 (fr) 2015-01-12 2015-12-03 Quinones pour la protection contre une exposition à des rayonnements

Country Status (2)

Country Link
JP (1) JP2018502127A (fr)
WO (1) WO2016114860A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202325B2 (en) 2011-07-19 2019-02-12 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US10251847B2 (en) 2014-12-16 2019-04-09 Bioelectron Technology Corporation Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10738014B2 (en) 2016-11-15 2020-08-11 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10968166B2 (en) 2007-11-06 2021-04-06 Ptc Therapeutics, Inc. 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US11174212B2 (en) 2018-10-17 2021-11-16 Ptc Therapeutics, Inc. 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11312697B2 (en) 2008-10-28 2022-04-26 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
US11786486B2 (en) 2021-07-08 2023-10-17 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281809A1 (en) 2005-06-01 2006-12-14 Miller Guy M Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2010045220A1 (fr) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Traitement d'affections liées au stress oxydatif, notamment de la néphropathie aux produits de contraste, des radiolésions et des perturbations de la fonction des globules rouges
US20100105930A1 (en) 2008-10-28 2010-04-29 Wesson Kieron E Process for the production of alpha-tocotrienol and derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281809A1 (en) 2005-06-01 2006-12-14 Miller Guy M Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2010045220A1 (fr) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Traitement d'affections liées au stress oxydatif, notamment de la néphropathie aux produits de contraste, des radiolésions et des perturbations de la fonction des globules rouges
US20100105930A1 (en) 2008-10-28 2010-04-29 Wesson Kieron E Process for the production of alpha-tocotrienol and derivatives

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Biological Approaches to the Controlled Delivery of Drugs", vol. 507, 1987, NEW YORK: NEW YORK ACADEMY OF SCIENCES
"Methods in Cell Biology", vol. XIV, 1976, ACADEMIC PRESS, pages: 33
"Physicians' Desk Reference (PDR", 1999
"Remington: The Science and Practice of Pharmacy", 2003, LIPPINCOTT WILLIAMS & WILKINS
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO.
"Symposium sponsored by Medicinal Chemistry Section, APhA Academy of Pharmaceutical Sciences, November 1976 national meeting, Orlando, Florida", 1977, WASHINGTON : THE ACADEMY, article "Design of Biopharmaceutical Properties Through Prodrugs and Analogs"
A KAGERUD ET AL: "TOCOPHEROL AND LOCAL X-RAY IRRADIATION OF TWO TRANSPLANTABLE RAT TUMOURS", CANCER LETTERS, 1 January 1978 (1978-01-01), pages 123, XP055245835, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S0304383578800287/pdf?md5=d12a589153d1915ff67fb890e21ee8d1&pid=1-s2.0-S0304383578800287-main.pdf> *
CARROLL ET AL., J. MED. CHEM., vol. 33, 1990, pages 2501
H. BUNDGAARD: "Design of Prodrugs", 1985, NEW YORK: ELSEVIER
KIMBERLY KRAMER-STICKLAND ET AL: "UV-B-Induced Photooxidation of Vitamin E in Mouse Skin", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 12, no. 2, 1 February 1999 (1999-02-01), US, pages 187 - 191, XP055246111, ISSN: 0893-228X, DOI: 10.1021/tx980204h *
LEE, DIFFUSION-CONTROLLED MATRIX SYSTEMS, pages 155 - 198
PIKE; ROBINSON, J. CELL PHYSIOL., vol. 76, 1970, pages 77 - 84
R. SILVERMAN: "The Organic Chemistry of Drug Design and Drug Action", 2004, BOSTON: ELSEVIER
RICHARD J HODGKISS ET AL: "THE EFFECT OF a-TOCOPHEROL AND a-TOCOPHERYL QUINONE ON THE RADIOSENSITIVITY OF THIOL-DEPLETED MAMMALIAN CELLS", INT J. RODRNMN ONCOLOGY BIOL PHY, 1 May 1989 (1989-05-01), pages 1291 - 1300, XP055246115, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/0360301689903027/pdf?md5=a54ca4f330ca93bd80acb68a3092c946&pid=1-s2.0-0360301689903027-main.pdf> [retrieved on 20160129] *
RON; LANGER: "Treatise on Controlled Drug Delivery", 1992, MARCEL DEKKER, INC., article "Erodible Systems", pages: 199 - 224
SNYDER, INT. J. RADIAT. BIOL., vol. 55, 1989, pages 773
SNYDER; LACHMANN, RADIATION RES., vol. 120, 1989, pages 121 - 128
WILLIAM D SHRADER ET AL: "alpha-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 12, 19 April 2011 (2011-04-19), pages 3693 - 3698, XP028387828, ISSN: 0960-894X, [retrieved on 20110424], DOI: 10.1016/J.BMCL.2011.04.085 *
WRIXON, A.D., J. RADIOL. PROT., vol. 28, 2008, pages 161 - 168

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968166B2 (en) 2007-11-06 2021-04-06 Ptc Therapeutics, Inc. 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US11840497B2 (en) 2007-11-06 2023-12-12 Ptc Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US11312697B2 (en) 2008-10-28 2022-04-26 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
US10202325B2 (en) 2011-07-19 2019-02-12 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US11304914B2 (en) 2014-12-16 2022-04-19 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10751302B2 (en) 2014-12-16 2020-08-25 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US11938101B2 (en) 2014-12-16 2024-03-26 Ptc Therapeutics, Inc. Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US10251847B2 (en) 2014-12-16 2019-04-09 Bioelectron Technology Corporation Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
US11560364B2 (en) 2015-12-16 2023-01-24 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US11186559B2 (en) 2015-12-16 2021-11-30 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11680034B2 (en) 2015-12-17 2023-06-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10981855B2 (en) 2015-12-17 2021-04-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10738014B2 (en) 2016-11-15 2020-08-11 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
US11390588B2 (en) 2016-11-15 2022-07-19 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US12281083B2 (en) 2016-11-15 2025-04-22 Ptc Therapeutics, Inc. 2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
US11174212B2 (en) 2018-10-17 2021-11-16 Ptc Therapeutics, Inc. 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11667596B2 (en) 2018-10-17 2023-06-06 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11746077B2 (en) 2018-10-17 2023-09-05 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
US11786486B2 (en) 2021-07-08 2023-10-17 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Also Published As

Publication number Publication date
JP2018502127A (ja) 2018-01-25

Similar Documents

Publication Publication Date Title
WO2016114860A1 (fr) Quinones pour la protection contre une exposition à des rayonnements
EP2362726B1 (fr) Traitement d&#39;affections liées au stress oxydatif, notamment de la néphropathie aux produits de contraste, des radiolésions et des perturbations de la fonction des globules rouges
Rasey et al. Radioprotection of Normal Tissues against Gamma Rays and Cyclotron Neutrons with WR-2721: LD50 Studies and Biodistribution
JP2019504018A (ja) 酸化ストレス障害を処置するためのフルオロアルキル、フルオロアルコキシ、フェノキシ、ヘテロアリールオキシ、アルコキシ、およびアミノ１，４−ベンゾキノン誘導体
US20020001565A1 (en) Radioprotective agents
Crouch et al. Chemical protection against x-radiation death in primates: a preliminary report
Brownell et al. Cocaine congeners as PET imaging probes for dopamine terminals
JP5553306B2 (ja) 放射線障害防護剤
US20150231093A1 (en) Methods and compositions for countermeasures against radiation
JP5512275B2 (ja) 放射線傷害治療のための三置換グリセロール化合物の使用
SE1350211A1 (sv) Metoder och kompositioner för behandling av cancermetastaser
EP1593127A2 (fr) Radioprotection au moyen de gamma-tocotrienol
Pedraza-López et al. Cytotoxic and genotoxic effect of the [166Dy] Dy/166Ho-EDTMP in vivo generator system in mice
US20180243327A1 (en) USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE
RU2179020C2 (ru) Радиозащитное средство
US8304439B1 (en) Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
EP2211857B1 (fr) Utilisation de sels de pyridinium quaternaire pour la radioprotection
Muravleva et al. MEDICAL RADIOLOGY AND RADIATION SAFETY
US20200268779A1 (en) USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION
EP2638902B1 (fr) Médicament antipaludique comprenant de l&#39;alaremycine ou un dérivé de celle-ci comme principe actif
WO1989009613A1 (fr) Agent de protection contre les effets des radiations
Valerievna et al. Study of the Allergizing Properties of Nanocolloid, 99mTc–Al2O3 Radiopharmaceutical in Experiment
JP2008137942A (ja) トコフェロールまたはトコトリエノール類のエステル誘導体を有効成分とする放射線防護剤
JP2015205835A (ja) 中性子線障害防護剤
WO2014037927A1 (fr) Compositions de chlorate et utilisation de chlorate dans le traitement de l&#39;exposition aux rayonnements

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15819928

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017536942

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15819928

Country of ref document: EP

Kind code of ref document: A1